Proprotein Convertase Subtilisin/Kexin Type 9 NewsLatest News On Proprotein Convertase Subtilisin/Kexin Type 9 PCSK9 Inhibitors Associated With Lower Nonmelanoma Skin Cancer Risk in Cohort Study12/6/2024 6:15 AM New PCSK9s Nearing Market Will Help Meet Cholesterol Targets7/24/2024 4:31 AM First Oral PCSK9 Shows Promise Lowering Cholesterol6/28/2024 6:41 AM Novel PCSK9 Drives High-Risk Patients to Target LDL6/26/2024 4:15 AM Novel PCSK9 Drives High-Risk Patients to Target LDL6/25/2024 4:23 AM Novel PCSK9 Inhibitor Reduced LDL by 50%4/18/2024 4:25 AM Earlier Inclisiran Gives Better Long-Term LDL Reductions4/17/2024 2:33 AM
